

Aza-Morita–Baylis–Hillman Reactions Catalyzed by a Cyclopropenylidene

Xun Lu and Uwe Schneider*

*The University of Edinburgh, EaStCHEM School of Chemistry,
The King's Buildings, David Brewster Road, Edinburgh EH9 3FJ, UK*

General and Additional Information

Table of Contents	Page
1 General Experimental	S–2
2 Additional Experiments	S–4
2.1 Control Experiments with <i>N</i> -Heterocyclic Carbenes (NHCs; Table S–1)	S–4
2.2 Control Experiments with <i>N</i> - and <i>P</i> -Centered Lewis Bases (Table S–2)	S–5
3 General Procedures	S–6
3.1 Synthesis of Bis(dialkylamino)cyclopropenylidene Salts 3a–d •HX	S–6
3.2 General Procedure for the Synthesis of Imines 4a–z	S–9
3.3 General Procedure for the Synthesis of Michael Acceptors 5b and 5e	S–10
3.4 General Procedures for BAC Catalysis	S–11
4 Analytical Data for Unknown Compounds	S–13
4.1 Analytical Data for Bis(dialkylamino)cyclopropenylidene Salts 3a–d •HX	S–13
4.2 Analytical Data for Imines 4a–z	S–14
4.3 Analytical Data for Michael Acceptors 5b and 5e	S–15
4.4 Analytical Data for Products 6a–z and (<i>R</i>)- 6a	S–16
4.5 Analytical Data for Products 6ab–aj	S–31
5 References	S–35
6 Copies of NMR Spectra of Substrates and Products	S–36
7 Copies of HPLC Charts	S–112

1 General Experimental

Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker AVA 400, Bruker AVA 500, Bruker PRO 500, and Bruker AVA 600 spectrometers, respectively. These spectrometers operate at the following frequencies: 400 MHz, 500 MHz, or 600 MHz for ^1H NMR; 100 MHz, 125 MHz, or 150 MHz for ^{13}C NMR; 128 MHz or 160 MHz for ^{11}B NMR; 128 MHz for ^{19}F NMR. Chemical shifts (δ) were quoted in parts per million (ppm) downfield to tetramethylsilane (TMS; $\delta = 0$ ppm), or in the scale relative to the corresponding NMR solvent used as an internal reference. Coupling constants (J) are quoted to the nearest 0.1 Hz. Abbreviations used in the description of resonances are: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet), m (multiplet), and br (broad). Infrared (IR) spectra were recorded on a Shimadzu IR Affinity-1 instrument using the corresponding isolated NMR sample in CDCl_3 (attenuated total reflectance sampling technique). High-resolution mass spectra (HRMS) were recorded on a Finnigan MAT 900 XLT spectrometer [electrospray ionization (ESI) technique]. Chiral HPLC analyses were performed on a Shimadzu LC-20AT apparatus with an SPD-20A detector using 4.6 x 250 mm columns from DAICEL CHIRALPAK. Thin-layer chromatography (TLC) was carried out on pre-coated silica gel plates from Merck (DF Alufolien 60F₂₅₄; 0.2 mm). Preparative thin-layer Chromatography (PTLC) was carried out on self-prepared plates using silica gel from Wakogel (B-5F; particle size: 45 μm). Flash column chromatography was carried out using silica gel from Fisher Scientific (60 Å; particle size: 40–63 μm). Product spots were visualized by UV light at 254 nm, or with an appropriate stain solution. Melting points were recorded on a Gallenkamp melting point apparatus (uncorrected).

All bases were purchased with the highest available purity: LiHMDS (97%, Aldrich), NaHMDS (99%, Aldrich), KHMDS (0.5 M in toluene, Aldrich), LDA (97%, Aldrich), LTMP (97%, Aldrich), NaO^tBu (99.9%, Aldrich), KO^tBu (99.99%, Aldrich), Li_2CO_3 ($\geq 99.0\%$, Aldrich), Na_2CO_3 ($\geq 99.0\%$, Aldrich), K_2CO_3 (99.9995%, Aldrich), Cs_2CO_3 (99.9995%, Aldrich), 1,8-diazabicyclo[5.4.0]undec-7-ene ($\geq 99.0\%$, Aldrich), *N,N,N,N*-tetramethylguanidine (TMG, $\geq 99.0\%$, Aldrich), proton sponge ($\geq 99.0\%$, Aldrich), 1,4-diazabicyclo[2.2.2]octane (DABCO; 99%, Aldrich), 4-dimethylaminopyridine (DMAP; $> 99\%$, Aldrich), triphenylphosphine (99%, Aldrich), tributylphosphine (99%, Aldrich), tricyclohexylphosphine (1 M in toluene, Aldrich). All NHC precursors for control experiments were purchased with the highest available purity: **1a**•HCl (95%, Aldrich), **1b**•HBF₄ (96%, Aldrich), **1c**•HBF₄ (97%, Aldrich), **1d**•HBF₄ (97%, Aldrich), **1e**•HCl (97%, Aldrich), **1f**•HBF₄ (95%, Aldrich), **1g**•HI (98%, Aldrich), **1h**•HBr ($\geq 98\%$, Aldrich) and **1i**•HBr (98%, Aldrich). CAAC precursor **2**•(HCl)₂ was donated from Rhodia (Marseille, France).

Bis(dialkylamino)cyclo-propenylidene precursors **3a**•HBF₄,¹ **3b**•HBPh₄,² **3c**•HBPh₄,² and **3d**•HBPh₄² were prepared according to slightly modified literature methods. Imines **4a,j,l,s-u**,³ **4b**,⁴ **4c-e,h,k,z**,⁵ **4f,p**,⁶ **4g**,⁷ **4m,q**,⁸ **4n-o**,⁹ **4r**,¹⁰ **4v**,¹¹ **4w**,¹² **4x-y**,¹³ are literature-known and were prepared accordingly. Imine **4h** was unknown and prepared according to a literature method.³ Michael acceptors **5a** (98%, Aldrich), **5c** (98%, Aldrich), **5d** (99%, Aldrich), **5f** (99%, Aldrich), **5g** (90%, Aldrich), **5h** (98%, Aldrich), **5i** (97%, Aldrich), and **5j** (99%, Aldrich) were purchased, distilled before use, and stored over activated molecular sieves (4 Å) in a nitrogen glove box. Michael acceptors **5b**¹⁴ and **5e**¹⁵ were prepared according to literature methods, respectively. The obtained analytical data were in full agreement with the reported data. Unless otherwise stated, all reagents purchased from commercial suppliers were used directly without further purification. THF, toluene, and diethyl ether were distilled over sodium–benzophenone, and stored over activated molecular sieves (4 Å) in a nitrogen glove box. All other solvents –including dioxane, DME, DCM, DCE, and MeCN– were used non-distilled, but stored over activated molecular sieves (4 Å) in a nitrogen glove box. Solvent dryness was confirmed using a Karl–Fischer apparatus.











All catalytic reactions were carried out in oven-dried glassware (sealed screw-capped test tubes) under an inert atmosphere. Conventional stirring and heating was carried out using a magnetic stirring bar and a hot plate magnetic stirrer (sand bath).

2 Additional Experiments

2.1 Control Experiments with *N*-Heterocyclic Carbenes (NHCs; Table S-1)

Results for the control experiments with NHCs –under optimized conditions– are summarized in Table S–1.

Table S-1: Control experiments with NHCs.^[a]




[a] The yield was determined by ¹H NMR spectroscopic analysis of an aliquot of the reaction mixture; internal standard: dibenzyl ether (25 mol% in mesitylene). [b] NR = no reaction; product **6a** was not detected – only starting materials were recovered (¹H NMR spectroscopic analysis of an aliquot of the reaction mixture).

2.2 Control Experiments with *N*- and *P*-Centered Lewis Bases (Table S–2)

Results for the control experiments with *N*- and *P*-centered Lewis bases –at 1 mol% catalyst loading– are summarized in Table S–2.

Table S–2: Control experiments with *N*- and *P*-centered Lewis bases.^[a]




^[a] The yield was determined by ¹H NMR spectroscopic analysis of an aliquot of the reaction mixture; internal standard: dibenzyl ether (25 mol% in mesitylene).

3 General Procedures


3.1 Preparation of Bis(dialkylamino)cyclopropenylidene Salts **3a–d**•HX

Bis(diisopropylamino)cyclopropenium tetrafluoroborate (**3a**•HBF₄)



The compound was prepared according to Bertrand's reported literature procedure.¹ Diisopropylamine (11.1 g, 110 mmol, 5.00 equiv) was added drop-wise to a stirred solution of tetrachlorocyclopropene (3.87 g, 22.0 mmol, 1.00 equiv) in CH₂Cl₂ (150 mL) at 0 °C under a nitrogen atmosphere. After 6 h at 0 °C, the solution was warmed to room temperature and sodium tetrafluoroborate (7.50 g, 22.0 mmol, 1.00 equiv) was added. The suspension was stirred overnight and refluxed for 4 h. After cooling to room temperature were added successively triphenylphosphine (5.71 g, 22.0 mmol, 1.00 equiv) and water (100 mL), and the mixture was stirred overnight (open air). The organic layer was washed with water (3 x 250 mL), dried (MgSO₄), and concentrated *in vacuo*. After washing with pentane (100 mL) and drying *in vacuo*, the solid obtained was recrystallized from CH₂Cl₂/Et₂O at –20 °C to give **3a**•HBF₄ as a yellow solid.


Bis(diethylamino)cyclopropenium tetraphenylborate (**3b**•HBPh₄)



The compound was prepared according to a reported literature procedure.² Diethylamine (4.70 mL, 45.0 mmol, 4.50 equiv) was added drop-wise to a stirred solution of tetrachlorocyclopropene (1.38 mL, 12.0 mmol, 1.00 equiv) in CH₂Cl₂ (200 mL) at –78 °C under a nitrogen atmosphere. The reaction mixture was warmed to room temperature over 3 h and cooled to –78 °C. Triphenylphosphine (2.96 g, 12.0 mmol, 1.00 equiv) was added quickly, and the mixture was warmed to room temperature. At that stage, distilled water (40 mL) was added, and the two-phase mixture was stirred vigorously for 16 h before adding sodium tetraphenylborate (3.86 g, 12.0 mmol, 1.00 equiv). The organic layer was successively washed with aqueous HCl (0.5 M; 15 mL), aqueous NaHCO₃ (saturated; 15


mL), and water (10 mL), dried (Na_2SO_4), and concentrated *in vacuo*. Recrystallization from hot MeOH gave **3b**•HBPh₄ as a colorless solid (4.30 g, 92% yield).

Bis(dicyclohexylamino)cyclopropenium tetraphenylborate (**3c**•HBPh₄)




The compound was prepared according to a modified literature procedure.² Dicyclohexylamine (5.14 mL, 45.0 mmol, 4.50 equiv) was added drop-wise to a stirred solution of tetrachlorocyclopropene (1.38 mL, 12.0 mmol, 1.00 equiv) in CH_2Cl_2 (200 mL) at $-78\text{ }^\circ\text{C}$ under a nitrogen atmosphere. The reaction mixture was warmed to room temperature over 3 h, distilled water (40 mL) was added, and the two-phase mixture was stirred vigorously for 16 h before adding sodium tetraphenylborate (3.86 g, 12.0 mmol, 1.00 equiv). The organic layer was successively washed with aqueous HCl (0.5 M; 15 mL), aqueous NaHCO_3 (saturated; 15 mL), and water (10 mL), dried (Na_2SO_4), and concentrated *in vacuo*. Recrystallization from hot MeOH gave the chlorocyclopropenium salt as a colorless solid (mp $132\text{--}133\text{ }^\circ\text{C}$). The chlorocyclopropenium salt (1.00 g, 1.30 mmol, 1.00 equiv) was dissolved in DCM (50 mL) and cooled to $-78\text{ }^\circ\text{C}$. Triphenylphosphine (0.35 g, 1.30 mmol, 1.00 equiv) was added quickly, and the mixture was warmed to room temperature. At that stage, distilled water (10 mL) was added, and the two-phase mixture was stirred vigorously for 16 h. The organic layer was successively washed with aqueous HCl (0.5 M; 20 mL), aqueous NaHCO_3 (saturated; 20 mL), and water (15 mL), dried (Na_2SO_4), and concentrated *in vacuo*. Recrystallization from DCM/Et₂O gave **3c**•HBPh₄ as a light-yellow solid.

2-(S)-1-Phenylethyl-7-[(S)-1-phenylethyl]-2,7-diazabicyclo[6.1.0]non-1(8)-en-9-ylum
tetraphenylborate (**3d**•HBPh₄)



The compound was prepared according to a reported literature procedure.² Under a nitrogen atmosphere, a pre-cooled solution of *N,N'*-bis[(*S*)-phenylethyl]butane-1,4-diamine²³ (83.0 mg, 0.28 mmol, 1.00 equiv) in CH₂Cl₂ (0.6 mL) at –78 °C was slowly added to a solution of tetrachlorocyclopropene (34.0 μL, 0.28 mmol, 1.00 equiv) in CH₂Cl₂ (5.0 mL) at –78 °C. After addition of diisopropylethylamine (98.0 μL, 0.56 mmol, 2.00 equiv), the reaction mixture was warmed to room temperature and stirred at room temperature for 3 h. The flask was cooled to –78 °C, at which stage polystyrene-bound triphenylphosphine (3.0 mmol/g; 100 mg, 0.56 mmol, 2.00 equiv) was added in one portion. The reaction mixture was warmed to room temperature over 2 h before successive addition of distilled water (5 mL) and sodium tetraphenylborate (98.0 mg, 0.28 mmol, 1.00 equiv). The reaction mixture was stirred vigorously for 48 h before filtration and transfer of the filtrate to a separating funnel containing CH₂Cl₂. After phase separation, the organic layer was washed successively with aqueous HCl (0.5 M), aqueous NaHCO₃ (saturated), and water. The organic phase was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on silica gel (eluent: acetone/DCM = 1:100) to obtain the pure product as a colorless solid (150 mg, 83% yield).


3.2 General Procedure for the Synthesis of Imines 4a–z



To an oven-dried 50 mL round-bottom flask with a magnetic stirring bar under an argon atmosphere were added *p*-toluenesulfonamide (1.00 equiv), tetraethyl orthosilicate (1.10 equiv), and the respective aldehyde (1.00 equiv). The flask was connected to a short distillation head (approximately 3–4 cm long) and a receptor flask. The reaction mixture was heated at 140–160 °C for 8–16 h; the by-product, ethanol, was collected in the receptor flask. After confirming the end-point of the reaction by ^1H NMR spectroscopic analysis, the reaction mixture was cooled to room temperature and washed with hexane (10 mL). The mixture was filtered, and volatiles were removed from the filtrate *in vacuo* to give a solid, which was recrystallized from ethyl acetate to yield the corresponding pure imine, which was powdered and dried over molecular sieves (4Å) in DCM prior to use in catalysis.


3.3 Procedures for the Synthesis of Michael Acceptors **5b** and **5e**

Procedure for the Synthesis of **5b**¹⁴



NBS (1.95 g, 11.0 mmol, 1.10 equiv) and AIBN (20.0 mg, 0.11 mmol, 0.01 equiv) were added to a solution of 1-indanone (1.32 g, 10.0 mmol, 1.00 equiv) in CCl₄ (4 mL). The resulting mixture was stirred at 100 °C for 2.5 h, cooled to room temperature, filtered through celite, and washed with CCl₄. The filtrate was cooled to 0 °C, treated with triethylamine (2.80 mL, 20.0 mmol, 2.00 equiv) overnight, and concentrated *in vacuo*. Flash column chromatography on silica gel (eluent: EtOAc/PE = 1:5) gave product **5b** as a yellow liquid (10.7 g, 90% yield).

Procedure for the Synthesis of **5e**¹⁵




Triethylamine (2.47 g, 24.0 mmol, 2.40 equiv) was added drop-wise over 1 h to a stirred solution of 3-chloropropiophenone (1.68 g, 10.0 mmol, 1.00 equiv) in chloroform (20 mL) under a nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature, followed by washing with aqueous HCl (1 M; 2 x 20 mL), distilled water (2 x 20 mL), aqueous NaHCO₃ (saturated; 2 x 20 mL), and brine (1 x 20 mL). The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (eluent: EtOAc/PE = 1:6) to give product **5e** as a colorless liquid (1.20 g, 90% yield).

3.4 General Procedures for BAC Catalysis

Deprotonation of 3a•HBF₄ and Formation of 3a•BEt₃

To an oven-dried test tube with a magnetic stirring bar in a nitrogen glovebox were added **3a**•HBF₄ (16.0 mg, 50 μmol, 1.00 equiv) and THF (400 μL). The reaction mixture was cooled to −78 °C and stirred for 15 min. KHMDs (0.5 M in toluene; 100 μL, 50 μmol, 1.00 equiv) was added drop-wise to the mixture, which was stirred at −78 °C for 15 min. The reaction mixture was warmed to room temperature and stirred for 30 min. Volatiles were removed *in vacuo*, and C₆D₆ (400 μL) was added to the test tube. The supernatant of the suspension was added to triethyl borane (1.0 M in hexane; 60.0 μL, 60 μmol, 1.20 equiv). The solution was then transferred to an NMR tube for ¹¹B NMR spectroscopic analysis; the upper chart corresponds to triethyl borane (BEt₃); the bottom chart corresponds to the formation of **3a**•BEt₃.



Procedure for Initial C–C Bond Formation

To an oven-dried test tube with a magnetic stirring bar in a nitrogen glovebox were added **3a**•HBF₄ (3.2 mg, 10 μmol, 1.00 equiv) and THF (80 μL). The reaction mixture was cooled to –78 °C and stirred for 15 min. KHMDs (20 μL, 10 μmol, 0.5 M in toluene, 1.00 equiv) was added dropwise to the mixture, and stirred at –78 °C for 15 min. The reaction mixture was warmed to room temperature and stirred for 30 min. Volatiles were removed *in vacuo*, and THF (100 μL) was added to the test tube to prepare a catalyst solution. To another oven-dried test tube with a magnetic stirring bar in a nitrogen glovebox were added imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv), Michael acceptor **5a** (8.2 mg, 0.10 mmol, 1.00 equiv), and THF (400 μL, 0.2 M in total). The reaction mixture was stirred at 30 °C for 24 h. ¹H NMR spectroscopic analysis was carried to detect the NMR yield of product **6a**.

General Procedure A [imine scope]

To an oven-dried test tube with a magnetic stirring bar in a nitrogen glovebox were added **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%), the corresponding imine (0.22 mmol, 1.10 equiv), Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv), THF (0.66 mL), and DBU (1.5 mg, 10 μmol, 5 mol%). The reaction mixture was stirred at 30 °C for 24–48 h, at which point TLC and/or ¹H NMR spectroscopic analysis indicated complete consumption of **5a**. Volatiles were removed *in vacuo*, and the residue was purified by PTLC or flash column chromatography on silica gel (eluent: EtOAc/PE = 1:2, or DCM/acetone = 100:1) to give the corresponding products.

General Procedure B [Michael acceptor scope]


To an oven-dried test tube with a magnetic stirring bar in a nitrogen glovebox were added **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%), imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv), the corresponding Michael acceptor (0.10 mmol, 1.00 equiv), THF (0.33 mL), and DBU (1.5 mg, 10 μmol, 10 mol%). The reaction mixture was stirred at 40 °C for 24–72 h, at which point TLC and/or ¹H NMR analysis indicated complete consumption of the corresponding Michael acceptor. The volatiles were removed *in vacuo*, and the residue was purified by PTLC or flash column chromatography on silica gel (eluent: EtOAc/PE = 1:5) to give the corresponding products.

4 Analytical Data for Unknown Compounds

4.1 Analytical Data for Bis(dialkylamino)cyclopropenylidene Salts 3a–d•HX

The synthesized BAC precursor **3b**•HBPh₄ and **3d**•HBPh₄ are literature-known,² and the obtained analytical data are in full agreement with the reported data. The obtained analytical data for the novel BAC precursors **3a**•HBF₄ and **3c**•HBPh₄ are listed below.

Bis(diisopropylamino)cyclopropenium tetrafluoroborate (**3a**•HBF₄)



Yellow solid (mp 132–134 °C).

Yield: 10.6 g (90%).

¹H NMR (CDCl₃, 600 MHz): δ = 7.46 (s, 1H), 4.05 (sept, *J* = 11.3 Hz, 2H), 3.86 (sept, *J* = 11.3 Hz, 2H), 1.41 (d, *J* = 11.3 Hz, 12H), 1.38 (d, *J* = 11.3 Hz, 12H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 133.8 (2C), 99.3, 56.9 (2C), 49.2 (2C), 20.8 (4C), 20.7 (4C) ppm.


¹¹B NMR (CDCl₃, 128 MHz): δ = −1.70 ppm.

¹⁹F NMR (CDCl₃, 128 MHz): δ = −152.2 ~ −152.3 (m) ppm.

IR (neat): ν = 3122, 2983, 2268, 1880, 1566, 1055, 1033, 912, 727 cm^{−1}.

HRMS (ESI⁺): calculated for C₁₅H₂₉N₂⁺ = [M]⁺: *m/z* = 237.2319, found: *m/z* = 237.2325.

Bis(dicyclohexylamino)cyclopropenium tetraphenylborate (**3c**•HBPh₄)



Light-yellow solid (mp 152–153 °C).

Yield: 0.81 g (85%).

¹H NMR (CDCl₃, 600 MHz): δ = 7.57 (br s, 8H), 7.09 (t, *J* = 8.5 Hz, 8H), 6.63 (t, *J* = 8.5 Hz, 4H), 4.61 (br s, 1H), 3.39 (q, *J* = 7.5 Hz, 2H), 3.36 (q, *J* = 7.5 Hz, 2H), 1.92–1.89 (m, 15H), 1.77–1.75 (m, 2H), 1.53–1.52 (m, 15H), 1.38–1.35 (m, 8H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 167.5 (q, *J* = 44.3 Hz, 4C), 138.9 (4C), 138.1 (2C), 127.5 (8C), 122.5 (8C), 99.2, 57.3 (4C), 31.2 (4C), 25.9 (8C), 25.4 (8C) ppm.

¹¹B NMR (CDCl₃, 160 MHz): δ = −6.14 ppm.


IR (neat): ν = 3110, 3045, 2984, 1620, 1593, 1567 cm^{−1}.

HRMS (ESI⁺): calculated for C₂₇H₄₅N₂⁺ = [M]⁺: *m/z* = 397.6578, found: *m/z* = 397.6581.

4.2 Analytical Data for Imines 4a–z

The synthesized imines **4a,j,l,s–u**,³ **4b**,⁴ **4c–e,h,k,z**,⁵ **4f,p**,⁶ **4g**,⁷ **4m,q**,⁸ **4n–o**,⁹ **4r**,¹⁰ **4v**,¹¹ **4w**,¹² **4x–y**,¹³ are literature-known, and the obtained analytical data are in full agreement with the reported data. The obtained analytical data for the novel imine **4i** are listed below.

4-Methyl-*N*-[(4-amino)benzylidene]benzenesulfonamide (**4i**)



Colorless liquid.

¹H NMR (CDCl₃, 500 MHz): δ = 9.72 (s, 1H), 7.73 (d, J = 7.0 Hz, 2H), 7.49 (d, J = 7.6 Hz, 2H), 7.33 (d, J = 7.0 Hz, 2H), 7.19 (d, J = 7.6 Hz, 2H), 6.39 (br s, NH₂, 2H), 2.32 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 168.1, 149.1, 144.3, 138.2, 132.7, 130.1 (2C), 129.7 (2C), 127.2 (2C), 114.3 (2C), 21.6 ppm.

IR (neat): ν = 3408, 2978, 2882, 1618, 1460, 1376, 1325, 1148, 856 cm⁻¹.


HRMS (ESI⁺): calculated for C₁₄H₁₄NaN₂O₂S = [M+Na]⁺: m/z = 297.0801, found: m/z = 297.0810.

4.3 Analytical Data for Michael Acceptors **5b** and **5e**

The synthesized Michael acceptors **5b**¹⁴ and **5e**¹⁵ are literature-known, and the obtained analytical data are in full agreement with the reported data.

4.4 Analytical Data for Products **6a–z** and (*R*)-**6a**

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(phenyl)methyl]benzenesulfonamide (**6a**)¹⁶




Prepared from imine **4a** (57.0 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.20 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6a** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 64.2 mg (93%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(2-toluy)l)methyl]benzenesulfonamide (**6b**)



Prepared from imine **4b** (60.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6b** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 163–165 °C).

Yield: 64.7 mg (91%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.60 (d, *J* = 8.4 Hz, 2H), 7.35 (t, *J* = 6.3 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 2H), 7.12–7.03 (m, 4H), 5.82 (d, *J* = 7.6 Hz, 1H), 5.49 (d, *J* = 7.6 Hz, 1H), 2.49–2.13 (m, 4H), 2.38 (s, 3H), 2.28 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 208.3, 160.2, 143.9, 143.2, 137.3, 136.7, 135.7, 130.7, 129.3 (2C), 127.9, 127.4 (2C), 126.9, 126.3, 51.8, 34.9, 26.7, 21.5, 19.4 ppm.

IR (neat): ν = 3302, 2958, 1697, 1441, 1339, 1161, 904, 864, 741, 650 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₀H₂₁NaNO₃S = [M+Na]⁺: *m/z* = 378.1134, found: *m/z* = 378.1120.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(3-toluy)methyl]benzenesulfonamide (**6c**)



Prepared from imine **4c** (60.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6c** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 164–165 °C).

Yield: 63.1 mg (87%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.61 (d, *J* = 8.2 Hz, 2H), 7.35 (t, *J* = 6.1 Hz, 1H), 7.19 (d, *J* = 8.2 Hz, 2H), 7.12–7.10 (m, 1H), 7.02 (d, *J* = 7.6 Hz, 1H), 6.93 (d, *J* = 7.6 Hz, 2H), 6.02 (d, *J* = 8.4 Hz, 1H), 5.25 (d, *J* = 8.4 Hz, 1H), 2.50–2.15 (m, 4H), 2.39 (s, 3H), 2.23 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 208.3, 160.4, 143.6, 143.1, 138.5, 138.3, 137.5, 129.3 (2C), 128.6, 128.5, 127.5, 127.4 (2C), 123.7, 55.4, 34.9, 26.7, 21.4, 21.3 ppm.

IR (neat): ν = 3275, 2920, 2849, 1695, 1437, 1330, 1159, 1091, 904, 815, 742, 665 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₀H₂₁NaNO₃S = [M+Na]⁺: *m/z* = 378.1134, found: *m/z* = 378.1115.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-toluy)methyl]benzenesulfonamide (**6d**)¹⁶




Prepared from imine **4d** (60.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.50 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6d** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 57.9 mg (84%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(2-naphthalenyl)methyl]benzenesulfonamide (6e)



Prepared from imine **4e** (68.2 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 48 h. **6e** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:1).

Colorless solid (mp 176–178 °C).

Yield: 77.2 mg (93%).


¹H NMR (CDCl₃, 600 MHz): δ = 8.07–8.06 (m, 1H), 7.84–7.82 (m, 1H), 7.76–7.74 (m, 1H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.49–7.47 (m, 2H), 7.42–7.41 (t, *J* = 6.3 Hz, 1H), 7.33–7.30 (m, 2H), 7.14 (d, *J* = 8.2 Hz, 2H), 6.10 (d, *J* = 7.8 Hz, 1H), 6.04 (d, *J* = 7.8 Hz, 1H), 2.46–2.19 (m, 4H), 2.39 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 208.4, 161.3, 143.4, 143.2, 137.0, 133.9, 130.3, 129.2 (2C), 128.9, 128.8, 127.5 (2C), 126.6, 126.2, 125.8, 125.3, 125.0, 123.1, 51.7, 34.9, 26.7, 21.4 ppm.

IR (neat): ν = 3163, 3005, 2943, 1440, 1375, 1037, 918, 748 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₃H₂₁NaNO₃S = [M+Na]⁺: *m/z* = 414.1134, found: *m/z* = 414.1111.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(2-naphthalenyl)methyl]benzenesulfonamide (6f)



Prepared from imine **4f** (68.2 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6f** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:1).

Colorless solid (mp 175–179 °C).

Yield: 76.2 mg (92%).

¹H NMR (CDCl₃, 500 MHz): δ = 7.76–7.75 (m, 1H), 7.70 (d, *J* = 8.6 Hz, 2H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.59 (s, 1H), 7.45–7.44 (m, 2H), 7.42 (t, *J* = 5.4 Hz, 1H), 7.31–7.30 (m, 1H),


7.10 (d, J = 8.2 Hz, 2H), 6.18 (d, J = 8.4 Hz, 1H), 5.45 (d, J = 8.4 Hz, 1H), 2.54–2.20 (m, 4H), 2.30 (s, 3H) ppm.

^{13}C NMR (CDCl_3 , 150 MHz): δ = 208.5, 160.8, 139.5, 137.9, 133.7, 133.0, 132.8, 129.7, 129.3 (2C), 128.6, 127.9, 127.5, 127.4 (2C), 126.4, 126.3, 125.7, 125.4, 58.1, 32.5, 26.2, 21.3 ppm.

IR (neat): ν = 3165, 3003, 2943, 1701, 1436, 1375, 1161, 1039, 918, 736, 669 cm^{-1} .

HRMS (ESI $^{+}$): calculated for $\text{C}_{23}\text{H}_{21}\text{NaNO}_3\text{S}$ = $[\text{M}+\text{Na}]^{+}$: m/z = 414.1134, found: m/z = 414.1093.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-methoxyphenyl)methyl]benzenesulfonamide (6g**)**¹⁶




Prepared from imine **4g** (63.8 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**• HBF_4 (3.2 mg, 10 μmol , 5 mol%) and DBU (1.5 mg, 10 μmol , 5 mol%) in THF (0.66 mL, 0.3 M) at 30 $^{\circ}\text{C}$ for 30 h. **6g** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 70.2 mg (92%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-dimethylaminophenyl)methyl]benzenesulfonamide (6h**)**¹⁷




Prepared from imine **4h** (67.1 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**• HBF_4 (3.2 mg, 10 μmol , 5 mol%) and DBU (1.5 mg, 10 μmol , 5 mol%) in THF (0.66 mL, 0.3 M) at 30 $^{\circ}\text{C}$ for 48 h. **6h** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁷

Pale-yellow solid.

Yield: 72.3 mg (92%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-aminophenyl)methyl]benzenesulfonamide (**6i**)



Prepared from imine **4i** (60.2 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6i** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 157–159 °C).

Yield: 59.2 mg (83%).


¹H NMR (CDCl₃, 500 MHz): δ = 8.65 (br s, 2H), 7.66 (d, *J* = 8.1 Hz, 2H), 7.40 (d, *J* = 8.1 Hz, 2H), 7.26 (t, *J* = 5.4 Hz, 1H), 7.05 (d, *J* = 8.2 Hz, 2H), 6.62–6.59 (m, 2H), 5.85 (d, *J* = 8.2 Hz, 1H), 5.21 (d, *J* = 8.2 Hz, 1H), 2.52–2.17 (m, 4H), 2.41 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 208.3, 151.1, 146.3, 141.5, 139.9, 132.7, 131.7 (2C), 131.2, 129.5 (2C), 129.1 (2C), 116.1 (2C), 60.7, 35.1, 28.8, 23.9 ppm.

IR (neat): ν = 3028, 2924, 2835, 2291, 2250, 1705, 1587, 1494, 1346, 1180, 914, 825, 750, 700, 663, 623 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₉H₂₀NaN₂O₃S = [M+Na]⁺: *m/z* = 356.4432, found: *m/z* = 356.4433.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-hydroxyphenyl)methyl]benzenesulfonamide (**6j**)



Prepared from imine **4j** (59.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6j** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 169–170 °C).

Yield: 50.0 mg (70%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.80 (d, *J* = 8.3 Hz, 2H), 7.52 (d, *J* = 8.1 Hz, 2H), 7.45 (t, *J* = 5.3 Hz, 1H), 7.26 (d, *J* = 8.3 Hz, 2H), 6.93–6.91 (m, 2H), 6.10 (d, *J* = 8.4 Hz, 1H), 5.83 (br s, 1H), 5.25 (d, *J* = 8.4 Hz, 1H), 2.55–2.19 (m, 4H), 2.43 (s, 3H) ppm.

^{13}C NMR (CDCl_3 , 125 MHz): δ = 206.3, 157.8, 144.3, 139.5, 137.7, 130.7, 129.8 (2C), 129.5 (2C), 127.6, 125.1 (2C), 115.1 (2C), 58.1, 32.5, 26.2, 21.3 ppm.

IR (neat): ν = 3062, 2922, 2835, 2250, 1705, 1647, 1587, 1435, 1346, 180, 750, 698, 611 cm^{-1} .

HRMS (ESI⁺): calculated for $\text{C}_{19}\text{H}_{19}\text{NaNO}_4\text{S}$ = $[\text{M}+\text{Na}]^+$: m/z = 380.5824, found: m/z = 380.5821.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-fluorophenyl)methyl]benzenesulfonamide (6k**)**¹⁶




Prepared from imine **4k** (71.0 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**• HBF_4 (3.2 mg, 10 μmol , 5 mol%) and DBU (1.5 mg, 10 μmol , 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6k** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 66.3 mg (91%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-chlorophenyl)methyl]benzenesulfonamide (6l**)**¹⁶




Prepared from imine **4l** (64.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**• HBF_4 (3.2 mg, 10 μmol , 5 mol%) and DBU (1.5 mg, 10 μmol , 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6l** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 72.3 mg (95%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-bromophenyl)methyl]benzenesulfonamide (6m**)**¹⁷




Prepared from imine **4m** (67.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6m** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁷

Colorless solid.

Yield: 80.2 mg (94%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-methoxycarbonylphenyl)methyl]benzenesulfonamide (6n**)**



Prepared from imine **4n** (69.8 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6n** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 181–183 °C).

Yield: 67.4 mg (94%).


¹H NMR (CDCl₃, 500 MHz): δ = 7.90 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 8.3 Hz, 2H), 7.36 (t, *J* = 5.3 Hz, 1H), 7.26 (d, *J* = 8.3 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 6.12 (d, *J* = 8.7 Hz, 1H), 5.34 (d, *J* = 8.7 Hz, 1H), 3.90 (s, 3H), 2.56–2.14 (m, 4H), 2.40 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 207.3, 165.6, 160.0, 142.5, 142.4, 141.8, 136.3, 128.9 (2C), 128.6, 128.4 (2C), 126.3 (2C), 125.7 (2C), 54.2, 51.1, 33.9, 25.9, 20.5 ppm.

IR (neat): ν = 3258, 3032, 2917, 1743, 1613, 1431, 1256, 1121, 1099, 910, 812, 732, 654 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₁H₂₁NaNO₅S = [M+Na]⁺: *m/z* = 422.5612, found: *m/z* = 466.5619.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-trifluoromethylphenyl)methyl]benzenesulfonamide (6o**)**



Prepared from imine **4o** (72.0 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6o** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 190–192 °C).

Yield: 76.4 mg (85%).

¹H NMR (CDCl₃, 500 MHz): δ = 7.58 (d, *J* = 8.2 Hz, 2H), 7.46 (d, *J* = 8.5 Hz, 2H), 7.37 (t, *J* = 5.9 Hz, 1H), 7.30 (d, *J* = 8.5 Hz, 2H), 7.18 (d, *J* = 8.2 Hz, 2H), 6.19 (d, *J* = 8.6 Hz, 1H), 5.36 (d, *J* = 8.6 Hz, 1H), 2.56–2.18 (m, 4H), 2.39 (s, 3H) ppm.


¹³C NMR (CDCl₃, 150 MHz): δ = 208.4, 161.1, 144.3, 143.5, 142.7, 137.3, 132.0 (q, *J* = 1.3 Hz, 2C), 130.7 (q, *J* = 270.3 Hz), 129.4 (2C), 128.9 (q, *J* = 3.8 Hz, 2C), 127.2 (2C), 125.5 (q, *J* = 32.5 Hz), 55.2, 34.9, 26.9, 21.4 ppm.

¹⁹F NMR (CDCl₃, 128 MHz): δ = – 62.7 (s, 3F) ppm.

IR (neat): ν = 3275, 2916, 2850, 1693, 1436, 1328, 1159, 906, 745, 665 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₀H₁₈F₃NaNO₃S = [M+Na]⁺: *m/z* = 432.0852, found: *m/z* = 432.0857.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-cyanophenyl)methyl]benzenesulfonamide (6p**)**



Prepared from imine **4p** (62.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6p** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 170–172 °C).

Yield: 67.8 mg (91%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.60 (d, *J* = 8.3 Hz, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.34 (t, *J* = 4.8 Hz, 1H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.22 (d, *J* = 8.3 Hz, 2H), 6.19 (d, *J* = 8.8 Hz, 1H), 5.33 (d, *J* = 8.8 Hz, 1H), 2.56–2.20 (m, 4H), 2.41 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 208.3, 161.4, 143.8, 143.7, 142.3, 137.7, 132.4 (2C), 129.5 (2C), 127.5 (2C), 127.3 (2C), 118.4, 111.8, 55.0, 34.9, 26.9, 21.5 ppm.

IR (neat): ν = 3319, 2898, 2819, 2234, 1716, 1672, 1567, 1423, 1398, 1189, 934, 783, 643 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₀H₁₈NaN₂O₃S = [M+Na]⁺: *m/z* = 389.5345, found: *m/z* = 389.5350.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-nitrophenyl)methyl]benzenesulfonamide (6q**)**^{16,17}




Prepared from imine **4q** (67.1 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6q** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*^{16,17}

Pale-yellow solid.

Yield: 72.3 mg (93%).

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(2-furanyl)methyl]benzenesulfonamide (6r**)**¹⁶




Prepared from imine **4r** (54.8 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6r** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Yellow solid.

Yield: 55.9 mg (83%).

4-Methyl-N-[(5-oxocyclopent-1-enyl)(2-thienyl)methyl]benzenesulfonamide (**6s**)



Prepared from imine **4s** (58.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. **6s** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Pale-yellow solid (mp 160–164 °C).

Yield: 70.4 mg (92%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.66 (d, *J* = 8.1 Hz, 2H), 7.41 (t, *J* = 5.2 Hz, 1H), 7.24 (d, *J* = 8.1 Hz, 2H), 7.16–7.15 (m, 1H), 6.86–6.84 (m, 1H), 6.78–6.77 (m, 1H), 6.03 (d, *J* = 9.0 Hz, 1H), 5.54 (d, *J* = 9.0 Hz, 1H), 2.56–2.17 (m, 4H), 2.41 (s, 3H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 208.1, 160.4, 143.4, 143.0, 142.3, 141.9, 137.4, 129.4 (2C), 127.4 (2C), 126.9, 125.4, 51.3, 34.9, 26.3, 21.5 ppm.

IR (neat): ν = 3163, 3001, 2943, 1735, 1442, 1375, 1246, 1039, 918, 748 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₇H₁₇NaNO₃S₂ = [M+Na]⁺: *m/z* = 370.0542, found: *m/z* = 370.0540.

4-Methyl-N-[(5-oxocyclopent-1-enyl)(2-pyrrolyl)methyl]benzenesulfonamide (**6t**)



Prepared from imine **4t** (54.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 48 h. **6t** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Brown solid (mp 145–147 °C).

Yield: 64.8 mg (88%).


¹H NMR (CDCl₃, 600 MHz): δ = 8.61 (br s, NH, 1H), 7.67 (d, *J* = 8.1 Hz, 2H), 7.46 (t, *J* = 5.6 Hz, 1H), 7.26 (d, *J* = 8.1 Hz, 2H), 7.25–7.23 (m, 1H), 6.15–6.13 (m, 1H), 6.02–6.01 (m, 1H), 5.86 (d, *J* = 9.0 Hz, 1H), 5.29 (d, *J* = 9.0 Hz, 1H), 2.55–2.29 (m, 4H), 2.42 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 206.8, 144.3, 137.9, 137.5, 130.9, 129.7 (2C), 128.6, 127.5 (2C), 123.5, 111.9, 110.3, 58.3, 32.9, 26.3, 20.9 ppm.

IR (neat): ν = 3001, 2941, 2252, 1707, 1440, 1375, 1346, 1182, 916, 754, 702 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₇H₁₈NaN₂O₃S = [M+Na]⁺: m/z = 353.5632, found: m/z = 353.5634.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(1*H*-indol-3-yl)methyl]benzenesulfonamide (**6u**)



Prepared from imine **4u** (65.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 48 h. **6u** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 175–179 °C).

Yield: 63.2 mg (83%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.68–7.65 (m, 2H), 7.60 (d, *J* = 8.1 Hz, 2H), 7.34 (t, *J* = 5.0 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 2H), 7.12–7.08 (m, 1H), 7.00–6.97 (m, 1H), 6.73–6.72 (m, 1H), 6.02 (d, *J* = 8.4 Hz, 1H), 5.17 (br s, NH, 1H), 4.20 (d, *J* = 8.4 Hz, 1H), 2.53–2.16 (m, 4H), 2.38 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 208.3, 146.3, 139.9, 139.0, 132.7, 131.7 (2C), 130.9, 129.8, 129.5 (2C), 127.7, 124.2, 124.1, 122.2, 121.3, 113.6, 60.1, 34.9, 28.6, 23.7 ppm.

IR (neat): ν = 2924, 2251, 1703, 1662, 1587, 1346, 1180, 914, 752, 696 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₁H₂₀NaN₂O₃S = [M+Na]⁺: m/z = 403.6171, found: m/z = 403.6174.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(1*H*-indol-1-carboxylic acid-3-yl)methyl]benzenesulfonamide (**6v**)



Prepared from imine **4v** (87.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg,

10 μ mol, 5 mol%) and DBU (1.5 mg, 10 μ mol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6v** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 189–194 °C).

Yield: 95.4 mg (89%).


¹H NMR (CDCl₃, 500 MHz): δ = 8.23 (d, J = 8.1 Hz, 1H), 8.02–8.00 (m, 1H), 7.78 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 8.1 Hz, 2H), 7.22–7.20 (m, 1H), 7.10–7.08 (m, 1H), 6.73 (t, J = 5.7 Hz, 1H), 6.08 (d, J = 8.4 Hz, 1H), 5.34 (d, J = 8.4 Hz, 1H), 2.54–2.18 (m, 4H), 2.39 (s, 3H), 1.44 (s, 9H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 206.3, 149.3, 144.3, 139.5, 135.4, 130.7, 129.7 (2C), 129.2, 128.5, 128.1, 127.6 (2C), 126.7, 122.9, 120.2, 119.2, 115.2, 81.4, 58.1, 32.5, 28.2, 26.2, 21.3 ppm.

IR (neat): ν = 3061, 3028, 2922, 2833, 2250, 1703, 1574, 1346, 1180, 914, 750, 698 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₆H₂₈NaN₂O₅S = [M+Na]⁺: m/z = 503.7325, found: m/z = 503.7330.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(4-pyridinyl)methyl]benzenesulfonamide (**6w**)



Prepared from imine **4v** (87.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μ mol, 5 mol%) and DBU (1.5 mg, 10 μ mol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 48 h. **6v** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Pale-yellow solid (mp 160–164 °C).

Yield: 95.4 mg (84%).


¹H NMR (CDCl₃, 500 MHz): δ = 8.55–8.53 (m, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.20–7.18 (m, 2H), 6.72 (t, J = 5.2 Hz, 1H), 6.02 (d, J = 8.4 Hz, 1H), 5.23 (d, J = 8.4 Hz, 1H), 2.58–2.22 (m, 4H), 2.40 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 206.3, 149.8, 144.3, 139.5, 137.9, 130.7, 130.0, 129.7 (2C), 129.4, 129.1, 127.6 (2C), 120.7, 57.9, 32.3, 25.9, 21.1 ppm.

IR (neat): ν = 3030, 2924, 2291, 2251, 1703, 1654, 1587, 1438, 1346, 1180, 1165, 914, 750 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₈H₁₈NaN₂O₃S = [M+Na]⁺: m/z = 365.5734, found: m/z = 365.5743.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(3-phenylpropyl)methyl]benzenesulfonamide (6x**)**



Prepared from imine **4x** (63.2 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6x** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 178–182 °C).

Yield: 75.0 mg (92%).


¹H NMR (CDCl₃, 500 MHz): δ = 7.69 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.28–7.25 (m, 2H), 7.17–7.14 (m, 3H), 6.69 (d, *J* = 5.4 Hz, 1H), 6.12 (d, *J* = 8.4 Hz, 1H), 4.93 (t, *J* = 8.4 Hz, 1H), 2.55–2.50 (m, 2H), 2.42 (s, 3H), 2.38–2.30 (m, 4H), 2.21 (q, *J* = 7.4 Hz, 2H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 208.4, 164.3, 144.3, 140.8, 130.8, 129.7 (2C), 129.1, 128.7 (2C), 128.4 (2C), 127.9, 127.5 (2C), 58.1, 32.9, 32.5, 30.7, 26.2, 21.3 ppm.

IR (neat): ν = 3324, 2976, 2913, 2876, 2423, 2231, 1897, 1701, 1687, 1512, 1428, 1387, 1176, 1143, 921, 754 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₁H₂₃NaNO₃S = [M+Na]⁺: *m/z* = 392.2453, found: *m/z* = 392.2459.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(3-cyclohexyl)methyl]benzenesulfonamide (6y**)**



Prepared from imine **4y** (58.4 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6y** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Pale-yellow solid (mp 130–132 °C).

Yield: 70.4 mg (91%).


¹H NMR (CDCl₃, 600 MHz): δ = 7.62 (d, *J* = 8.1 Hz, 2H), 7.23 (d, *J* = 8.1 Hz, 2H), 7.00 (t, *J* = 5.4 Hz, 1H), 5.72 (d, *J* = 8.9 Hz, 1H), 3.81 (dd, *J* = 8.9, 9.3 Hz, 1H), 2.40 (s, 3H), 2.39–2.38 (m, 1H), 2.19–2.18 (m, 1H), 2.09–2.08 (m, 1H), 1.96–1.95 (m, 2H), 1.94–1.92 (m, 4H), 1.42–1.39 (m, 1H), 1.15–1.10 (m, 3H), 0.90–0.81 (m, 2H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 209.1, 160.6, 142.9, 141.9, 137.9, 129.2 (2C), 127.4 (2C), 57.4, 40.8, 34.8, 29.9, 29.4 (2C), 26.6 (2C), 26.1, 21.4 ppm.

IR (neat): ν = 3396, 3176, 2997, 2941, 1597, 1575, 1411, 1375, 1037, 918, 688 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₉H₂₅NaNO₃S = [M+Na]⁺: *m/z* = 370.1447, found: *m/z* = 370.1438.

4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(2,2-dimethylpropyl)methyl]benzenesulfonamide (6z**)**



Prepared from imine **4z** (52.6 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3a**•HBF₄ (3.2 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 30 h. **6z** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2).

Colorless solid (mp 106–110 °C).

Yield: 56.8 mg (78%).


¹H NMR (CDCl₃, 500 MHz): δ = 7.60 (d, *J* = 8.1 Hz, 2H), 7.21 (d, *J* = 8.1 Hz, 2H), 6.99 (t, *J* = 5.4 Hz, 1H), 5.70 (d, *J* = 8.1 Hz, 1H), 4.95 (d, *J* = 8.1 Hz, 1H), 2.50–2.14 (m, 4H), 2.32 (s, 3H), 0.82 (s, 9H) ppm.

¹³C NMR (CDCl₃, 150 MHz): δ = 206.1, 144.3, 137.9, 130.7, 129.7 (2C), 129.4, 127.5 (2C), 57.8, 35.4, 32.2, 26.3 (3C), 26.2, 20.9 ppm.

IR (neat): ν = 3401, 3198, 2978, 2939, 2897, 1603, 1577, 1423, 1398, 1365, 1045, 923, 712, 685 cm⁻¹.

HRMS (ESI⁺): calculated for C₁₇H₂₃NaNO₃S = [M+Na]⁺: *m/z* = 344.5376, found: *m/z* = 344.5381.

(*R*)-4-Methyl-*N*-[(5-oxocyclopent-1-enyl)(phenyl)methyl]benzenesulfonamide[(*R*)-6a**]²⁴**



Prepared from imine **4a** (57.0 mg, 0.22 mmol, 1.10 equiv) and Michael acceptor **5a** (16.4 mg, 0.20 mmol, 1.00 equiv) according to the *general procedure A* using **3d**•HBF₄ (6.50 mg, 10 μmol, 5 mol%) and DBU (1.5 mg, 10 μmol, 5 mol%) in THF (0.66 mL, 0.3 M) at 30 °C for 24 h. (*R*)-**6a** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:2). *The obtained analytical data was in full agreement with the reported data and the absolute configuration was assigned in analogy.*²⁴


Colorless solid.

Yield: 53.8 mg (78%), 35% ee.

The enantiomeric excess was determined by chiral HPLC analysis using a DAICEL Chiracel IB column (eluent: hexane/PrOH = 80:20; flow rate: 0.8 mL/min; 220 nm, 25 °C): t_r (S) = 10.8 min, t_r (R) = 12.9 min.

4.5 Analytical Data for Products **6ab–aj**

4-Methyl-*N*-[(inden-1-one)(phenyl)methyl]benzenesulfonamide (**6ab**)



Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5b** (12.5 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 24 h. **6ab** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5).

Colorless solid (mp 172–177 °C).

Yield: 39.1 mg (90%).


¹H NMR (CDCl₃, 500 MHz): δ = 7.98 (t, *J* = 5.2 Hz, 1H), 7.77–7.70 (m, 3H), 7.61–7.59 (m, 2H), 7.57–7.54 (m, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.27–7.19 (m, 5H), 6.15 (d, *J* = 9.3 Hz, 1H), 5.09 (d, *J* = 9.3 Hz, 1H), 2.32 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 194.5, 144.3, 143.5, 139.5, 137.9, 133.7, 130.7, 129.7 (2C), 129.2 (2C), 128.9 (2C), 128.6, 128.4, 127.5 (2C), 127.0, 126.9, 126.1, 121.7, 58.1, 21.4 ppm.

IR (neat): ν = 3394, 3214, 2989, 2902, 2896, 1954, 1756, 1698, 1585, 1432, 1376, 1389, 1187, 916, 787, 698 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₃H₁₉NaNO₃S = [M+Na]⁺: *m/z* = 412.2145, found: *m/z* = 412.2152.

4-Methyl-*N*-[(6-oxocyclohex-1-enyl)(phenyl)methyl]benzenesulfonamide (**6ac**)¹⁶




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5c** (10.4 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 48 h. **6ac** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*¹⁶

Colorless solid.

Yield: 66.7 mg (92%).

4-Methyl-N-(2-methoxoyl-1-benzylallyl)benzenesulfonamide (6ad**)**¹⁸




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5d** (8.2 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 48 h. **6ad** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*¹⁸

Colorless solid.

Yield: 30.8 mg (95%).

4-Methyl-N-(2-benzoyl-1-benzylallyl)benzenesulfonamide (6ae**)**¹⁹




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5e** (13.1 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 72 h. **6ae** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*¹⁹

Colorless solid.

Yield: 37.4 mg (94%).

Methyl-α-Methylene-β-[(p-toluenesulfonyl)-amino]-3-phenylpropionate (6af**)**^{20,21}




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5f** (9.3 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 72 h. **6af** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*^{20,21}

Colorless solid.

Yield: 32.1 mg (93%).

1-Naphthyl-2-[phenyl-(toluene-4-sulfonylamino)methyl]acrylate (6ag**)**^{20,21}




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5g** (19.8 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 48 h. **6ag** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:3). *The obtained analytical data were in full agreement with the reported data.*^{20,21}

Colorless solid.

Yield: 41.9 mg (96%).

2-[Phenyl-(toluene-4-sulfonylamino)methyl]-acrylamide (6ah**)**²²




Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5h** (7.1 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 72 h. **6ah** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*²⁴

Colorless solid.

Yield: 29.3 mg (88%)

2-[Phenyl-(toluene-4-sulfonylmorpholinyl)methyl]acrylamide (**6ai**)



6ai

Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5i** (14.1 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 72 h. **6ai** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5).

Colorless solid (mp 156–159 °C).

Yield: 33.1 mg (74%).


¹H NMR (CDCl₃, 500 MHz): δ = 7.60 (d, *J* = 8.7 Hz, 2H), 7.32 (d, *J* = 8.7 Hz, 2H), 7.26–7.22 (m, 3H), 7.14–7.11 (m, 2H), 6.26 (d, *J* = 8.1 Hz, 1H), 6.19 (s, 1H), 5.94 (s, 1H), 5.70 (d, *J* = 8.1 Hz, 1H), 3.64–3.57 (m, 8H), 2.32 (s, 3H) ppm.

¹³C NMR (CDCl₃, 125 MHz): δ = 166.7, 144.3, 139.6, 137.6, 129.7, 129.2, 128.9 (2C), 128.6 (2C), 127.6 (2C), 126.9 (2C), 114.3, 66.4 (2C), 58.1, 44.1 (2C), 21.3 ppm.

IR (neat): ν = 3421, 3100, 3080, 2975, 2635, 1682, 1645, 1523, 1459, 1324, 1130, 990, 910, 720 cm⁻¹.

HRMS (ESI⁺): calculated for C₂₁H₂₄N₂O₄NaS = [M+Na]⁺: *m/z* = 400.4965, found: *m/z* = 400.4974.

4-methyl-*N*-(2-Cyano-1-phenylpropen-2-yl)benzenesulfonamide (**6aj**)²⁰



6aj

Prepared from imine **4a** (28.5 mg, 0.11 mmol, 1.10 equiv) and Michael acceptor **5j** (5.3 mg, 0.10 mmol, 1.00 equiv) according to the *general procedure B* using **3b**•HBPh₄ (5.0 mg, 10 μmol, 10 mol%) and DBU (1.5 mg, 10 μmol, 10 mol%) in THF (0.33 mL, 0.3 M) at 40 °C for 48 h. **6aj** was purified by PTLC on silica gel (eluent: EtOAc/PE = 1:5). *The obtained analytical data were in full agreement with the reported data.*²⁰




Colorless solid.

Yield: 30.1 mg (96%).


5 References

- (1) V. Lavallo, Y. Canac, B. Donnadiou, W. W. Schoeller and G. Bertrand, *Science*, 2006, **312**, 722.
- (2) M. M. D. Wilde and M. Gravel, *Angew. Chem., Int. Ed.*, 2013, **52**, 1.
- (3) J. H. Wynne, S. E. Price, J. R. Rorer and W. M. Stalick, *Synth. Commun.*, 2003, **2**, 341.
- (4) K. D. Hesp, R. G. Bergman and J. A. Ellman, *Org. Lett.*, 2012, **14**, 2304.
- (5) R. Fan, D. Pu, P. Wen, Y. Ye and X. Wang, *J. Org. Chem.*, 2008, **73**, 3623.
- (6) Y. Dan, B. Zhou, J.-H. Lin and J.-C. Xiao, *Chem. Commun.*, 2015, **51**, 13127.
- (7) T. Regiani, V. G. Santos, M. N. Godoi, B. G. Vaz, M. N. Eberlin and F. Coelho, *Chem. Commun.*, 2011, **47**, 6593.
- (8) L. O. Planes, C. R. Escrich and M. A. Pericàs, *Chem. – Eur. J.*, 2014, **20**, 2367.
- (9) B. Zhou, Y. Yang, S. Lin and Y. Li, *Adv. Synth. Catal.*, 2013, **355**, 360.
- (10) Y.-W. Sun, X.-Y. Tang and M. Shi, *Chem. Commun.*, 2015, **51**, 13937.
- (11) I. P. Andrews and O. Kwon, *Chem. Sci.*, 2012, **3**, 2510.
- (12) M. H. Sarvari and H. Sharghi, *Phosphorus, Sulfur and Silicon*, 2007, **182**, 2125.
- (13) Z. Cui, H.-J. Yu, R.-F. Yang, W.-Y. Gao, C.-G. Feng and G.-Q. Lin, *J. Am. Chem. Soc.*, 2011, **133**, 12394.
- (14) S. Zhang, H. Tan, X. Zhang, C. Yu and Z. Shen, *Tetrahedron Lett.*, 2014, **5**, 975.
- (15) X. J. Tang, Z. Zhang and W. R. Dolbier, *Chem. – Eur. J.*, 2015, **21**, 18961.
- (16) L. He, T.-Y. Jian and S. Ye, *J. Org. Chem.*, 2007, **72**, 7466.
- (17) M. Shi, Y.-M. Xu, G.-L. Zhao and X.-F. Wu, *Eur. J. Org. Chem.*, 2002, **2002**, 3666.
- (18) M. Shi and Y.-M. Xu, *Eur. J. Org. Chem.*, 2002, **2002**, 696.
- (19) M. Shi and Y.-M. Xu, *J. Org. Chem.*, 2003, **68**, 4784.
- (20) D. Balan and H. Adolfsson, *J. Org. Chem.*, 2001, **66**, 6498.
- (21) M. Shi and Y.-M. Xu, *J. Org. Chem.*, 2004, **69**, 417.
- (22) Z. Wu, G. Zhou, J. Zhou and W. Guo, *Synth. Commun.*, 2006, **36**, 2491.
- (23) V. M. Mastranzo, L. Quintero, C. A. de Parrodi, E. Juaristi and P. L. Walsh, *Tetrahedron*, 2004, **60**, 1781.
- (24) M. Shi, Y.-M. Xu and Y.-L. Shi, *Chem. Eur. J.*, 2005, **11**, 1794.


6 Copies of NMR Spectra of Substrates and Products




¹¹B NMR





¹⁹F NMR









3b•HBPh₄





¹¹B NMR







¹¹B NMR







3d•BPh₄






¹¹B NMR










4a









4b























4e









































































4s








4t











4v













4x








4y











5b








5e










6a









6b

















6e














6f






























































6r








6s








6t








6u








6v








6w








6x








6y








6z








6ab








6ac








6ad








6ae








6af








6ag








6ah








6ai







6aj





(*R*)-6a



7 Copies of HPLC Charts

08/09/2016 11:14:13 Page 1 / 1




Analysis Report

<Sample Information>


Sample Name : XLrac_80_20
 Sample ID :
 Data Filename : XLrac_80_20.lcd
 Method Filename : 10min_wash.lcm
 Batch Filename :
 Vial # : 1-1
 Injection Volume : 20 uL
 Date Acquired : 24/06/2014 10:00:51
 Date Processed : 24/06/2014 10:27:49

Sample Type : Unknown

Acquired by : System Administrator
 Processed by : System Administrator



<Chromatogram>



<Peak Table>

Detector A 254nm

Peak#	Ret. Time	Area	Height	Mark	Name	Area%
1	10.748	10780289	979690	M		49.651
2	12.954	10931896	709817	M		50.349
Total		21712185	1689507			100.000

C:\LabSolutions\Data\XL\XunLu single runs\XLrac_80_20.lcd

SHIMADZU
LabSolutions

Analysis Report

IB Hex: 'R04' = 80.20. 0.8 ml/min

asymmetrical


<Sample Information>

Sample Name : XLasy8_80_20
 Sample ID :
 Data Filename : XLasy8_80_20.lcd
 Method Filename : 10min_wash.lcm
 Batch Filename :
 Vial # : 1-1
 Injection Volume : 20 µL
 Date Acquired : 24/06/2014 10:34:46
 Date Processed : 24/06/2014 10:54:15

Sample Type : Unknown
 Acquired by : System Administrator
 Processed by : System Administrator

<Chromatogram>

mV



<Peak Table>

Detector A 254nm						
Peak#	Ret. Time	Area	Height	Mark	Name	Area%
1	10.754	529381	24443	M		32.440
2	12.971	1102476	28675	M		67.560
Total		1631857	53118			100.000

35.1/see

C:\LabSolutions\Data\XL\XunLu single runs\XLasy8_80_20.lcd